A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
937actual
Sites
7
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-23 | actual | When the study began enrolling |
| Primary completion | 2026-05-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-29 | actual | The whole study's end, after follow-up |
| First posted | 2025-07-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Coronavirus Disease 2019 (COVID-19)
Intervention
- Drug: Nirmatrelvir/Ritonavir — also filed as Paxlovid
Primary outcome
what the primary-completion date above is the date OFComposite outcome of progression to severe disease or all-cause mortality within 30 days
measured During index date, defined as 30 days from COVID-19 symptom onset. Index period: 14 Jan 2022 to 1 June 2025 (or latest date available)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed